#USA #New York #Acquisition #Select Medical #Bleichmar Fonti

Select Medical Acquisition Sparks Legal Investigation

On June 9, 2026, the prominent securities law firm Bleichmar Fonti & Auld LLP announced its efforts to probe into the dealings of Select Medical Holdings Corporation's board of directors. This inquiry comes on the heels of the company's recent announcement about a planned acquisition at a price of $16.50 per share—an announcement that has raised several eyebrows within the investor community.

Background of the Investigation

The acquisition deal is orchestrated by a coalition including Robert A. Ortenzio, a co-founder of Select Medical, along with Senior Executive Vice President Martin F. Jackson and the private equity firm Welsh, Carson, Anderson & Stowe. Concerns arise particularly from the fact that while the merger offers public shareholders cash for their shares, certain key insiders, including Ortenzio and Jackson, have the option to maintain stakes in the post-merger entity. This creates a disparity that has prompted questions regarding fairness and the fiduciary responsibilities owed to shareholders who will only receive cash.

The investigation focuses on whether the board and senior management may have neglected their fiduciary duties during the negotiation and announcement of this merger. The key point of contention lies in the manner in which the deal was structured, particularly the allowance for certain insiders to “rollover” their shares, a privilege not extended to other shareholders.

Implications of the Merger

The details of the merger were approved by a special committee within the company’s board and are now contingent upon shareholder approval, which is set for June 26, 2026. The timeline raises issues about the potentially limited opportunities for shareholders to adequately assess the deal's fairness prior to voting. This investigation aims to ensure that all legal avenues are explored to guarantee shareholders are not unfairly treated.

In a climate where transparency and equity in corporate governance are increasingly under scrutiny, this case brings the practices of Select Medical's board into a critical spotlight. Shareholders deserve clarity regarding how crucial decisions are made and the extent to which their interests are genuinely represented in board discussions and resolutions.

Actions for Affected Shareholders

Current shareholders of Select Medical are encouraged to consider their legal options concerning the merger agreement. Bleichmar Fonti & Auld LLP is actively seeking to gather information from affected shareholders who may wish to participate in legal actions related to the potential breaches of fiduciary duty by the board.

It's important for those holding shares in Select Medical to understand their rights in this situation. The law firm emphasizes that representation is on a contingency fee basis, meaning there would be no upfront costs for shareholders looking to engage in this matter.

About Bleichmar Fonti & Auld LLP

Bleichmar Fonti & Auld LLP has built a reputation as a leading international law firm specializing in securities class actions and shareholder litigation. Recognized as a top plaintiff firm by numerous prestigious publications, they have successfully navigated complex litigation cases, recovering significant sums for other shareholders in past actions.

For any shareholders who might have concerns or seek more information, Bleichmar Fonti & Auld LLP invites engagement through their established platform for inquiries related to this investigation. The firm aims to uphold shareholder rights and ensure that fairness prevails in this acquisition.

In conclusion, the unfolding narrative of Select Medical's acquisition brings to light critical questions of governance and accountability that resonate across corporate America today. Shareholders must remain vigilant and informed as this situation develops, recognizing the importance of their role in shaping corporate policy and governance.